Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice

Susan Lucak, Lin Chang, Albena Halpert, Lucinda A. Harris

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard® and EnteraGam®). Given the lack of a standard treatment algorithm for IBS-D and the emergence of new pharmacologic therapies, treatment needs to be tailored to the individual patient and take into account the severity of disease. In this context, the latter part of this manuscript examines how treatments for IBS-D can be used in clinical practice by presenting three patient case scenarios with varying degrees of IBS-D severity. For each case, the patient's medical history and clinical presentation are related to the Rome Foundation multidimensional clinical profile (MDCP) and potential treatment options with current and emergent therapies are reviewed. The interplay of gastrointestinal symptoms and their psychosocial impact, as well as the importance of a patient-centered approach to therapy, are discussed. Consideration is given to the potential need for combination therapies and how emergent treatments could fit into the treatment pathway for mild, moderate, and severe cases of IBS-D in clinical practice.

Original languageEnglish (US)
Pages (from-to)253-275
Number of pages23
JournalTherapeutic Advances in Gastroenterology
Volume10
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Therapeutics
rifaximin
Gastrointestinal Diseases

Keywords

  • case management
  • clinical practice
  • irritable bowel syndrome with diarrhea
  • multimodal
  • pharmacologic treatment
  • severity
  • treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea : Evidence-based treatment in practice. / Lucak, Susan; Chang, Lin; Halpert, Albena; Harris, Lucinda A.

In: Therapeutic Advances in Gastroenterology, Vol. 10, No. 2, 2017, p. 253-275.

Research output: Contribution to journalReview article

@article{f2c51d96f667479ab052c94cc2695620,
title = "Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice",
abstract = "Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard{\circledR} and EnteraGam{\circledR}). Given the lack of a standard treatment algorithm for IBS-D and the emergence of new pharmacologic therapies, treatment needs to be tailored to the individual patient and take into account the severity of disease. In this context, the latter part of this manuscript examines how treatments for IBS-D can be used in clinical practice by presenting three patient case scenarios with varying degrees of IBS-D severity. For each case, the patient's medical history and clinical presentation are related to the Rome Foundation multidimensional clinical profile (MDCP) and potential treatment options with current and emergent therapies are reviewed. The interplay of gastrointestinal symptoms and their psychosocial impact, as well as the importance of a patient-centered approach to therapy, are discussed. Consideration is given to the potential need for combination therapies and how emergent treatments could fit into the treatment pathway for mild, moderate, and severe cases of IBS-D in clinical practice.",
keywords = "case management, clinical practice, irritable bowel syndrome with diarrhea, multimodal, pharmacologic treatment, severity, treatment",
author = "Susan Lucak and Lin Chang and Albena Halpert and Harris, {Lucinda A.}",
year = "2017",
doi = "10.1177/1756283X16663396",
language = "English (US)",
volume = "10",
pages = "253--275",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea

T2 - Evidence-based treatment in practice

AU - Lucak, Susan

AU - Chang, Lin

AU - Halpert, Albena

AU - Harris, Lucinda A.

PY - 2017

Y1 - 2017

N2 - Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard® and EnteraGam®). Given the lack of a standard treatment algorithm for IBS-D and the emergence of new pharmacologic therapies, treatment needs to be tailored to the individual patient and take into account the severity of disease. In this context, the latter part of this manuscript examines how treatments for IBS-D can be used in clinical practice by presenting three patient case scenarios with varying degrees of IBS-D severity. For each case, the patient's medical history and clinical presentation are related to the Rome Foundation multidimensional clinical profile (MDCP) and potential treatment options with current and emergent therapies are reviewed. The interplay of gastrointestinal symptoms and their psychosocial impact, as well as the importance of a patient-centered approach to therapy, are discussed. Consideration is given to the potential need for combination therapies and how emergent treatments could fit into the treatment pathway for mild, moderate, and severe cases of IBS-D in clinical practice.

AB - Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard® and EnteraGam®). Given the lack of a standard treatment algorithm for IBS-D and the emergence of new pharmacologic therapies, treatment needs to be tailored to the individual patient and take into account the severity of disease. In this context, the latter part of this manuscript examines how treatments for IBS-D can be used in clinical practice by presenting three patient case scenarios with varying degrees of IBS-D severity. For each case, the patient's medical history and clinical presentation are related to the Rome Foundation multidimensional clinical profile (MDCP) and potential treatment options with current and emergent therapies are reviewed. The interplay of gastrointestinal symptoms and their psychosocial impact, as well as the importance of a patient-centered approach to therapy, are discussed. Consideration is given to the potential need for combination therapies and how emergent treatments could fit into the treatment pathway for mild, moderate, and severe cases of IBS-D in clinical practice.

KW - case management

KW - clinical practice

KW - irritable bowel syndrome with diarrhea

KW - multimodal

KW - pharmacologic treatment

KW - severity

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85011370920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011370920&partnerID=8YFLogxK

U2 - 10.1177/1756283X16663396

DO - 10.1177/1756283X16663396

M3 - Review article

AN - SCOPUS:85011370920

VL - 10

SP - 253

EP - 275

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 2

ER -